Opthea Stock Today
| OPT Stock | USD 3.33 0.00 0.00% |
Performance4 of 100
| Odds Of DistressOver 76
|
Opthea is selling for under 3.33 as of the 28th of November 2024; that is No Change since the beginning of the trading day. The stock's last reported lowest price was 3.27. Opthea has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. Equity ratings for Opthea are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 29th of October 2024 and ending today, the 28th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 12th of April 2012 | Category Healthcare | Classification Health Care |
Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia. Opthea operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange.. The company has 153.89 M outstanding shares of which 73.55 K shares are now shorted by investors with about 1.88 days to cover. More on Opthea
Moving against Opthea Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Opthea Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Old Name | Optizen Labs SA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Australia All Ordinaries, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsOpthea can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Opthea's financial leverage. It provides some insight into what part of Opthea's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Opthea (OPT) is traded on NASDAQ Exchange in USA. It is located in 650 Chapel Street, South Yarra, VIC, Australia, 3141 and employs 33 people. Opthea is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a total capitalization of 509.26 M. Opthea runs under Biotechnology sector within Health Care industry. The entity has 153.89 M outstanding shares of which 73.55 K shares are now shorted by investors with about 1.88 days to cover.
Opthea has about 44.63 M in cash with (161.02 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.01.
Check Opthea Probability Of Bankruptcy
Ownership AllocationOpthea owns a total of 153.89 Million outstanding shares. Roughly 96.43 pct. of Opthea outstanding shares are held by general public with 3.57 (%) by third-party entities. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Opthea Ownership Details
Opthea Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Vgi Partners Pty Ltd | 2024-06-30 | 2.9 M | |
| Teacher Retirement System Of Texas | 2024-09-30 | 0.0 | |
| Baker Bros Advisors Lp | 2024-09-30 | 2.2 M | |
| Millennium Management Llc | 2024-06-30 | 71.2 K | |
| Bank Of Montreal | 2024-06-30 | 48.6 K | |
| Bmo Capital Markets Corp. | 2024-06-30 | 48.6 K | |
| Stratos Wealth Partners, Ltd | 2024-09-30 | 29.6 K | |
| Royal Bank Of Canada | 2024-06-30 | 6 K | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 0.0 | |
| Frazier Financial Advisors, Llc | 2024-09-30 | 0.0 | |
| Jane Street Group Llc | 2024-06-30 | 0.0 |
Opthea Historical Income Statement
Opthea Stock Against Markets
Opthea Corporate Management
| Jen Watts | VP Operations | Profile | |
| Karen CPA | VP Secretary | Profile | |
| CPA CPA | Chief Officer | Profile | |
| MD MA | Chief Advisor | Profile | |
| Sarika Gulhar | Executive Resources | Profile | |
| Michael Gerometta | Manufacturing Chemistry | Profile | |
| Peter MBA | Chief Officer | Profile |
Additional Tools for Opthea Stock Analysis
When running Opthea's price analysis, check to measure Opthea's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Opthea is operating at the current time. Most of Opthea's value examination focuses on studying past and present price action to predict the probability of Opthea's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Opthea's price. Additionally, you may evaluate how the addition of Opthea to your portfolios can decrease your overall portfolio volatility.